Product Information
- 2-Methyl-3-[(2E,6E,10E,14E,18E,22E,26E,30E,34E,38E,42E,46E)-3,7,11,15,19,23,27,31,35,39,43,47,51-tridecamethyl-2,6,10,14,18,22,26,30 ,34,38,42,46,50-dopentacontatridecaenyl]-1,4-naphthalenedioneMK 13
- 1,4-Naphthalenedione,2-methyl-3-(3,7,11,15,19,23,27,31,35,39,43,47,51-tridecamethyl-2,6,10,14,18,22,26,30,34,38,42,46,50-dopentacontatridecaenyl)-,(all-E)-
- 1,4-Naphthoquinone,2-methyl-3-(3,7,11,15,19,23,27,31,35,39,43,47,51-tridecamethyl-2,6,10,14,18,22,26,30,34,38,42,46,50-dopentacontatridecaenyl)-(8CI)
- Mk 13
Menaquinone 13 is a vitamin K2 that is involved in the post-translational carboxylation of the glutamic acid residues on specific proteins. It has been shown to be a potent inhibitor of epidermal growth factor (EGF) and can be used for the treatment of cancer. Menaquinone 13 inhibits bacterial growth by binding to DNA-dependent RNA polymerase, thereby preventing transcription and replication. The high frequency of human activity has been shown using a patch-clamp technique on human erythrocytes. This active form is metabolized through a number of metabolic transformations, including hydrolysis by esterases or glucuronidases, oxidation by cytochrome P450 enzymes, reduction by glutathione reductase, or conjugation with glucuronic acid. Menaquinone 13 also specifically binds to markers expressed at high levels in Mycobacterium tuberculosis strains (e.g., ESX-1 secretion system protein) and inhibits
